Company Announcements & Press Releases

Press Releases and Company Announcements published before 1 May 2017 in Swedish only.

Latest news

17 January, 2019

RhoVac reports positive interim immune-results in the follow-up phase of company’s phase I/II clinical study

RhoVac AB (“RhoVac”) reported today, 17th January 2019, positive interim immune-results on 3- and 6-month’s follow-up testing in their phase I/II clinical study RhoVac-001 in prostate cancer patients. In the...[läs mer]

Older Company Announcements

17 December, 2018

RhoVac announces that the first patient completed the follow-up phase of the clinical phase I / II study

RhoVac AB (“RhoVac”) announce today, 17th December 2018, that the first prostate cancer patient included in the clinical phase I / II study with RhoVac’s drug candidate RV001 has completed...[läs mer]

14 November, 2018

RhoVac participates in international business conferences in the UK and the United States

RhoVac AB (“RhoVac”) will participate in J.P. Morgan Healthcare Conference in San Francisco, USA in January 2019 and at the Jefferies London Healthcare Conference, UK, 14-15 November 2018. From 7th...[läs mer]

18 September, 2018

RhoVac recruits Steven Glazer as Medical Director

RhoVac AB (“RhoVac”) announced today, September 18, 2018, that the company has recruited Dr. Steven Glazer to the position of Medical Director (MD), commencing immediately. Steven Glazer has been recruited...[läs mer]

17 August, 2018

RhoVac AB participates in two international conferences and several investment events in Sweden

RhoVac AB (“RhoVac”) announces today that it will attend Nordic Life Science Days, Stockholm in September and at BIO-Europe, Copenhagen in November. The company will also attend three investment events...[läs mer]

1 August, 2018

RhoVac’s reports positive results in the company’s phase I/II clinical study

RhoVac AB (“RhoVac”) reported today, August 1, 2018, positive top-line results on safety and on immune activation in their phase I/II clinical trial RhoVac-001 in prostate cancer patients. In totally...[läs mer]

9 July, 2018

Summer greetings from RhoVac

In 2015, RhoVac AB (“RhoVac”) launched a focused three-year plan aimed at developing the company’s drug candidate RV001, an immuno-oncology treatment, with the potential to prevent or limit the spread...[läs mer]

19 June, 2018

RhoVac’s reports positive and constructive response from the European Medicines Agency in the now completed Scientific Advice Procedure

RhoVac AB (“RhoVac”) announced today, June 19, 2018, that the company has received response from the European Medicines Agency (EMA) on the Scientific Advice Procedure. EMA has stated that there...[läs mer]

7 June, 2018

RhoVac’s rights issue heavily oversubscribed – subscribed to 196 percent

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL....[läs mer]

4 June, 2018

Interview with Gunnar Gårdemyr, new board member at RhoVac

At the annual general meeting on 9, May 2018, Gunnar Gårdemyr has been elected as the new board member of RhoVac AB “RhoVac”. Here is an interview with Gunnar Gårdemyr....[läs mer]